Replies to post #41265 on Biotech Values

[rhaab]

YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer

http://www.cnxmarketlink.com/en/releases/archive/January2007/30/c2871.html

The Data Safety Monitoring Board advises the trial is very unlikely to demonstrate a survival benefit for the tesmilifene arm

Conference call scheduled for Wednesday, January 31, 8:30 a.m. ET